Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TNGX
- Price
- 1.41
- Stock movement up
- +0.12 (8.88%)
- Company name
- Tango Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 151.46M
- Ent value
- 221.56M
- Price/Sales
- 3.49
- Price/Book
- 0.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -81.12%
- 3 year return
- -43.93%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TNGX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.49 |
| Price to Book | 0.66 |
| EV to Sales | 5.11 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 107.42M |
| EPS (TTM) | -1.14 |
| FCF per share (TTM) | -1.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 43.38M |
| Gross profit (TTM) | 41.51M |
| Operating income (TTM) | -139.70M |
| Net income (TTM) | -123.39M |
| EPS (TTM) | -1.14 |
| EPS (1y forward) | -1.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.68% |
| Operating margin (TTM) | -322.00% |
| Profit margin (TTM) | -284.43% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 53.15M |
| Net receivables | 0.00 |
| Total current assets | 300.81M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 352.42M |
| Accounts payable | 4.11M |
| Short/Current long term debt | 34.76M |
| Total current liabilities | 37.58M |
| Total liabilities | 123.25M |
| Shareholder's equity | 229.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -122.32M |
| Capital expenditures (TTM) | 856.00K |
| Free cash flow (TTM) | -123.18M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -53.84% |
| Return on Assets | -35.01% |
| Return on Invested Capital | -53.18% |
| Cash Return on Invested Capital | -53.09% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.31 |
| Daily high | 1.42 |
| Daily low | 1.27 |
| Daily Volume | 352K |
| All-time high | 17.30 |
| 1y analyst estimate | 11.50 |
| Beta | 0.88 |
| EPS (TTM) | -1.14 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| TNGX | S&P500 | |
| Current price drop from All-time high | -91.85% | -12.89% |
| Highest price drop | -93.01% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -57.90% | -11.07% |
| Avg time to new high | 77 days | 12 days |
| Max time to new high | 896 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
151.46M
Marketcap category
Small-cap
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Employees
140
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page